TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. SaveneT is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing.
| Website | http://www.topotarget.com |
| Revenue | $23 million |
| Employees | View employees |
| Address | 280 High Holborn, London, Greater London WC1V 7EE, GB |
| Phone | +44 20 3077 5700 |
| Industry | Pharmaceuticals, Healthcare, Drug Manufacturing & Research, Biotechnology |
| Competitors | Johnson & Johnson, Roche, Novartis, Sanofi, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Pfizer, Lilly India +48 more (view full list) |
| SIC | SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541711 Companies, NAICS Code 54 Companies |
Looking for a particular TopoTarget employee's phone or email?
TopoTarget Questions
The TopoTarget annual revenue was $23 million in 2026.
TopoTarget is based in London, Greater London.
The NAICS codes for TopoTarget are [541, 5417, 54171, 541711, 54].
The SIC codes for TopoTarget are [2834, 28, 283].
Related Companies
